FluxMPS™ MEM, Low Glucose with Earle's Salts

FluxMPS™ MEM, Low Glucose with Earle's Salts

FluxMPS™ MEM, Low Glucose with Earle's Salts (DCP-MEM-N1X) is a Microfluidics Suitable, quadruple-stage ultra-filtered Minimum Essential Medium formulated for organ-on-a-chip (OoC), microphysiological system (MPS), and microfluidic channel applications where conventional 0.22 µm single-pass media falls short. Manufactured under an ISO 13485:2016 quality management system and filled in an ISO Class 5 (Class 100) aseptic environment, the formulation reaches a 0.04 µm final cut-off through a validated four-stage sequential train, five times finer than conventional 0.22 µm sterile filtration.

• Quadruple-stage filtration train (0.1 µm ×2 + 0.04 µm ×2) reaching a 0.04 µm final cut-off — Microfluidics Suitable, not a single-pass 0.22 µm product
• Low glucose (1.0 g/L D-Glucose) with Earle's Salts, L-Glutamine (292 mg/L) and Sodium Pyruvate (110 mg/L) pre-included for metabolic flux and Warburg-effect studies
• Endotoxin release specification < 0.05 EU/mL (LAL, USP <85> BET), tested per manufacturing batch
• Sodium Bicarbonate-buffered (2,200 mg/L) with Phenol Red pH indicator (11 mg/L); requires a CO₂-supplemented incubator — contact Diagnocine for the validated CO₂ percentage
• Manufactured under an ISO 13485:2016 quality management system; final packaging and QC at Diagnocine, Totowa, NJ
• 0.1 µm mycoplasma-retentive filtration applied at two points in the train (not tested per lot)
• Available in 500 mL and 1000 mL; custom pH, glucose concentration, salts, HEPES, and nutrient composition available on request — contact support@diagnocine.com

Engineered where standard media fails

Conventional 0.22 µm-filtered media was designed for flask culture — not the nanoscale geometries of organ-on-a-chip devices, biosensor arrays, or perfusion bioreactors. Sub-visible particulates (2–20 µm), residual bioburden-sized debris, and micro-aggregates can block microchannels, coat optical surfaces, corrupt electrochemical signals, and introduce batch-to-batch variance. FluxMPS™ addresses these failure modes through a purpose-built, four-stage filtration architecture that reaches a 0.04 µm final cut-off.^[1,2]

Quadruple-stage filtration system

FluxMPS™ MEM is filtered to a final 0.04 µm pore size through a four-stage sequential train — two dedicated prefilter + final-filter pairs run in series. Each 0.04 µm final filter is protected by its own 0.1 µm prefilter, giving full redundancy across the train rather than a single descending cascade.

1. 1

   0.1 µm Prefiltration I

   Large particulate, cell-debris, and protein-aggregate removal; protects the first 0.04 µm cartridge.

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass; retains sub-micron particulates and microaggregates that pass a 0.22 µm filter.

3. 3

   0.1 µm Prefiltration II

   Second dedicated prefilter, protecting the second 0.04 µm cartridge.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate polishing filter; aseptic fill in an ISO Class 5 (Class 100) environment directly into sterile containers.

Validated across advanced in-vitro platforms

FluxMPS™ MEM, Low Glucose with Earle's Salts is designed for demanding MPS, organ-on-a-chip, and precision in-vitro platforms where media purity affects experimental outcomes. Its low-glucose formulation makes it particularly suited for metabolic research, cancer biology, and applications requiring user-defined carbon-source control.^[3,4]

Automated Bioreactors & Robotics

For automated perfusion bioreactors and robotic liquid-handling platforms, an optional 0.01 µm (10 nm) MPS Grade ultra nano-filtered variant of this formulation is available — a separate tier from the Microfluidics Suitable product described on this page — designed to reduce nano-particulate fouling of precision valves, sensors, and microfluidic tubing over extended continuous runs.

• Total Particulate Exclusion — the 0.01 µm MPS Grade variant adds 0.02 µm and 0.01 µm stages after the 0.04 µm polish, protecting pressure sensors and proportional valves
• Valve & Sensor Protection — reduced particulate loading limits wear on elastomeric micro-valves and electrode surfaces during multi-week automated perfusion runs
• Extended Perfusion Stability — consistent formulation over the full 12-month shelf life supports automated scheduling without lot-to-lot re-optimization

Inquiry Required: The 0.01 µm (10 nm) MPS Grade tier is produced on a make-to-order basis. Contact support@diagnocine.com to request it and discuss throughput, format, and lead-time requirements.

Quality-controlled parameters — per-lot release

Parameters below are measured on every production lot at Diagnocine's R&D and Quality Testing Center in Totowa, NJ. Results are documented in the lot-specific Certificate of Analysis (CoA).

Full composition (mg/L)

Complete ingredient listing per lot-release specification. All values are per liter of 1X final medium. Manufactured under ISO 13485:2016 QMS with per-lot release CoA available on request.

Manufacturing standards & compliance

FluxMPS™ MEM is manufactured under an ISO 13485:2016-certified Quality Management System, with final packaging, quality assurance, and testing performed at Diagnocine's R&D and Quality Testing Center in Totowa, New Jersey, USA.

How DCP-MEM-N1X compares

FluxMPS™ MEM (DCP-MEM-N1X) versus conventional 0.22 µm-filtered MEM and a standard single-pass 0.1 µm MEM alternative.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ MEM, Low Glucose with Earle's Salts (DCP-MEM-N1X).

Supporting literature

Peer-reviewed publications supporting the scientific basis for organ-on-a-chip applications with MEM, filtration architecture, metabolic research in low-glucose media, and mycoplasma control strategies.

1. Huh D, Matthews BD, Mammoto A, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662–1668.doi:10.1126/science.1188302
2. Zhang B, Radisic M. Organ-on-a-chip devices advance to market. Lab Chip. 2017;17(14):2395–2420.doi:10.1039/C7LC00248C
3. Maoz BM, Herland A, FitzGerald EA, et al. A linked organ-on-chip model of the human neurovascular unit. Nat Biotechnol. 2018;36(9):865–874.doi:10.1038/nbt.4226
4. Eagle H. Amino acid metabolism in mammalian cell cultures. Science. 1959;130(3373):432–437.doi:10.1126/science.130.3373.432
5. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect. Science. 2009;324(5930):1029–1033.doi:10.1126/science.1160809
6. Jang KJ, Mehr AP, Hamilton GA, et al. Human kidney proximal tubule-on-a-chip. Integr Biol (Camb). 2013;5(9):1119–1129.doi:10.1039/c3ib40049b
7. Langford DT, Waldron JA. Mycoplasma contamination of cell cultures. J Appl Bacteriol. 1985;59(5):483–491.doi:10.1111/j.1365-2672.1985.tb03349.x
8. Ewart L, Apostolou A, Briggs SA, et al. Performance assessment of a human Liver-Chip. Commun Med. 2022;2(1):154.doi:10.1038/s43856-022-00209-1
9. Bein A, Shin W, Jalili-Firoozinezhad S, et al. Microfluidic organ-on-a-chip models of human intestine. Cell Mol Gastroenterol Hepatol. 2018;5(4):659–668.doi:10.1016/j.jcmgh.2017.12.010
10. Bhise NS, Ribas J, Manoharan V, et al. Organ-on-a-chip platforms for studying drug delivery systems. J Control Release. 2014;190:82–93.doi:10.1016/j.jconrel.2014.05.004